October 10, 2023

Oregon State University is joining ResearchMatch! ResearchMatch is a national registry of patients interested in volunteering for medical research. This registry was developed by academic institutions across the country with the purpose of connecting research study teams with potential research patients. For more information on using ResearchMatch for your study, please visit our ResearchMatch page.

August 15, 2023

The FDA has posted new guidance intended to assist institutional review boards (IRBs), clinical investigators, and sponsors in complying with FDA’s informed consent regulations for clinical investigations. The guidance is available on FDA's website.

November 1, 2022

The OSU IRB has launched Cayuse HE for IRB applications! All researchers will now use Cayuse HE to submit their applications for review and approval. For more information on how previously approved studies (in iRIS or email-based) will be handled, please visit the Cayuse Human Ethics Transition page.

October 6, 2022

FDA Announces Harmonization Efforts. The FDA has announced two proposed rules that demonstrate their efforts toward harmonizing their human subject protection regulations with the HHS Common Rule for the kinds of research the FDA oversees. The proposed rules address cooperative research and requirements for single IRB review and enhanced requirements for the informed consent process for clinical trials.

October 3, 2022

The HRPP is no longer accepting submissions in iRIS in preparation for the transition to the new electronic IRB submission system, Cayuse HE. The HRPP and IRB will not be able to review any submissions until Cayuse is launched on October 28, 2022. Please visit the Cayuse Human Ethics Transition page to read more about this process. 

October 3, 2022

The OSU Library has posted a comprehensive guide on complying with NIH's Data Management and Sharing Policy. The policy applies to human subjects research funded by the NIH, will come into effect on January 25, 2023, and will cover grant applications for the January 25, 2023 cycle and all subsequent grant cycles.

September 13, 2022- HRPP Preparing for Cayuse!
In preparation for the Cayuse Human Ethics implementation, the HRPP has already begun revising key components of the IRB submission and review process. Researchers may have noticed the following significant changes in iRIS: 
  1. The HRPP is no longer utilizing the “Flex” review category for new applications; instead, the HRPP reviews an application to first determine whether it qualifies for a category of exempt research.  
  2. For projects determined to be exempt, the recruitment and consent/assent materials are no longer reviewed during the determination process and are also no longer stamped. 
  3. For studies of all review levels, researchers are no longer required to submit CVs by default; the IRB may still request them in some cases to evaluate the skills and qualifications of research personnel conducting certain activities.  
  4. Non-OSU collaborators are no longer required to have a DINO account in iRIS. They will still need to be listed in the personnel section of the application, but they no longer need an account to log in to the electronic submission system. 

The new application form in Cayuse will retain the above changes and also incorporate the following major changes:  

  • Researchers will be able to request that their study be evaluated for exemption, which will result in a shorter application and will not require them to submit materials for recruitment and consent processes. If the HRPP determines the study does not qualify for exemption, the researcher will be asked to complete the full application. Please note all activities for the study must fall under one or more categories of exempt research in order for the study to be exempt. 
  • The requirement for all study personnel to sign-off on IRB submissions has been eliminated. The PI is still required to certify all submissions.
August 22, 2022

FDA Publishes Responses to Good Clinical Practice Inquiries. FDA oversees clinical trials to ensure they are designed, conducted, analyzed and reported according to federal law and FDA’s regulations. The agency addresses inquiries related to good clinical practice and human subject protection policies on an ongoing basis. To read the most recent inquiries and responses, please use this link to FDA’s Good Clinical Practice Inquiries.

July 31, 2022

The Human Research Protections Program will be transitioning to a new electronic submission system, Cayuse, in the fall of 2022. This change is part of a broader effort by the Research Office to improve user experience with the IRB submission process and to integrate research integrity functions with OSU pre-award administration. You can read more about the Research Office plans here

Please continue to check back here for updated information and as further details and guidance become available, including the go-live date.